SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.
A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies.
"Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution," said Sam Raha, incoming president and CEO of Myriad Genetics. "He will be a critical member of our leadership team and will play an instrumental role in scaling our business, accelerating product adoption, and driving sustained profitable growth."
"I'm thrilled to join Myriad Genetics, which has such a deep commitment to advancing genetic insights and plays a critical role in empowering patients, physicians, and partners with the information needed to improve health outcomes," said Donnelly. "I look forward to working alongside this talented team to expand our impact, foster innovation, and accelerate the company's growth while staying true to Myriad's mission of advancing health and well-being for all."
Prior to joining Myriad Genetics, Donnelly held senior commercial and general management roles at leading organizations such as Ancestry, Amazon, and Illumina, successfully driving business growth across global markets and product lines. His ability to align commercial efforts with organizational goals, enhance brand positioning, and deliver shareholder value makes him well-positioned to build on Myriad's mission.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostics testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that Mr. Donnelly will be a critical member of the company's leadership team and will play an instrumental role in scaling the company's business, accelerating product adoption, and driving sustained profitable growth. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
